Seizure solver- pyridoxine dependent seizures

Vijay Ganesh, Manish Taneja, SangeethaMagna 2024 · DOI

Abstract

Pyridoxine dependency is a rare cause of seizures. Pyridoxine dependent seizures (PDS) occur despite normal vitamin B6 levels and is due to defective binding of pyridoxine to its apoenzyme, glutamate decarboxylase, which converts glutamic acid to gamma aminobutyric acid (GABA). Pyridoxine-dependent seizure is a rare autosomal recessive disorder that usually presents with neonatal intractable seizures. Parenteral pyridoxine injection test is a highly effective and reproducible test in confirming the diagnosis. Hunt, et al.(l) described the first case of PDS with autosomal recessive inheritance. Since then, several cases have been reported with onset of seizures after neonatal period (2-6). Pyridoxine-dependent epilepsy – ALDH7A1 (PDE-ALDH7A1) is characterized by seizures not well controlled with anti-seizure medication that are responsive clinically and electrographically to large daily supplements of pyridoxine (vitamin B6). This is true across a phenotypic spectrum that ranges from classic to atypical PDE-ALDH7A1. Intellectual disability is common, particularly in classic PDE-ALDH7A1.(7)

Introduction

Neonatal seizures represent a critical clinical emergency, frequently associated with sepsis, birth asphyxia, or metabolic disturbances. A particularly challenging subset of these cases involves refractory seizures that do not respond to standard anti-epileptic drugs (AEDs). Pyridoxine-Dependent Seizures (PDS) is a rare autosomal recessive metabolic disorder that clinicians must consider in such scenarios. Unlike typical vitamin deficiencies, PDS occurs in patients with normal systemic Vitamin B6 levels; the pathology lies in a genetic defect that impairs the binding of pyridoxine to glutamate decarboxylase. This enzyme is essential for synthesizing gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter. A lack of GABA leads to uncontrolled electrical activity and intractable epilepsy.

Case Presentation and Methods

This report details the case of a 4-day-old male neonate presenting with multifocal generalized seizures and shock-like symptoms, including hypotension and bradycardia. The diagnostic and therapeutic pipeline included:

  1. Stabilization: Initial management focused on resuscitation for hypotension and hypoglycemia, followed by the administration of second-line AEDs.
  2. Therapeutic Trial: Following 48 hours of failed AED treatment, a 100mg intravenous trial of pyridoxine was administered.
  3. Diagnostic Workup: MRI, EEG, and CSF analysis were conducted to exclude structural abnormalities or infectious causes like meningitis.
  4. Genetic Confirmation: Definitive diagnosis was sought through Whole Exome Sequencing (WES) and subsequent Sanger validation to identify mutations in the ALDH7A1 gene.

Results and Clinical Insights

The administration of 100mg IV pyridoxine resulted in the dramatic cessation of seizures within minutes. This clinical response was mirrored electrographically, as the abnormal burst spike patterns (>25Hz) on the EEG normalized immediately.

The "pyridoxine trial" serves as both a life-saving intervention and a powerful diagnostic tool. While this patient presented with atypical features such as shock and hypoglycemia, the rapid response to B6 highlighted the necessity of maintaining a high index of suspicion for PDS in all refractory neonatal seizure cases.

Genetic analysis provided the definitive diagnosis. WES identified a homozygous mutation in the ALDH7A1 gene (chr5:125930704C>A; p.Gly63Ter), which leads to a deficiency in the enzyme α-aminoadipic semialdehyde dehydrogenase.

Table 1: Genetic analysis results for the ALDH7A1 variant.

The patient remained seizure-free and was discharged on a lifelong maintenance dose of oral pyridoxine, a critical outcome for preventing the severe intellectual disability often associated with untreated PDS.

Discussion and Conclusion

This case underscores the transition toward precision diagnostics in neonatal neurology. The identification of the specific homozygous mutation (c.187G>T) in ALDH7A1 confirms the clinical diagnosis and dictates a clear, effective treatment path.

A primary limitation of this study is its nature as a single-patient case report, which limits statistical generalizations regarding the prevalence of specific ALDH7A1 variants. However, the clinical implications are significant. The authors recommend that pediatric status epilepticus protocols be updated to include a mandatory trial of pyridoxine for all children under the age of three presenting with intractable seizures. Early intervention is paramount to improving long-term neurodevelopmental outcomes in these rare but treatable genetic conditions.

Summary updated

Abstract

Pyridoxine dependency is a rare cause of seizures. Pyridoxine dependent seizures (PDS) occur despite normal vitamin B6 levels and is due to defective binding of pyridoxine to its apoenzyme, glutamate decarboxylase, which converts glutamic acid to gamma aminobutyric acid (GABA). Pyridoxine-dependent seizure is a rare autosomal recessive disorder that usually presents with neonatal intractable seizures. Parenteral pyridoxine injection test is a highly effective and reproducible test in confirming the diagnosis. Hunt, et al.(l) described the first case of PDS with autosomal recessive inheritance. Since then, several cases have been reported with onset of seizures after neonatal period (2-6). Pyridoxine-dependent epilepsy – ALDH7A1 (PDE-ALDH7A1) is characterized by seizures not well controlled with anti-seizure medication that are responsive clinically and electrographically to large daily supplements of pyridoxine (vitamin B6). This is true across a phenotypic spectrum that ranges from classic to atypical PDE-ALDH7A1. Intellectual disability is common, particularly in classic PDE-ALDH7A1.(7)
BibTeX
@inproceedings{ganesh2024seizure,
  author = {Vijay Ganesh and Manish Taneja and Sangeetha},
  title = {{Seizure solver- pyridoxine dependent seizures}},
  booktitle = {Magna},
  year = {2024},
  doi = {10.30574/msarr.2024.12.1.0156},
}
Figure